AZN Stock Overview
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines.
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£100.76|
|52 Week High||UK£115.40|
|52 Week Low||UK£80.90|
|1 Month Change||-11.33%|
|3 Month Change||-6.70%|
|1 Year Change||14.07%|
|3 Year Change||46.05%|
|5 Year Change||98.39%|
|Change since IPO||1,417.47%|
Recent News & Updates
|AZN||GB Pharmaceuticals||GB Market|
Return vs Industry: AZN exceeded the UK Pharmaceuticals industry which returned -1.3% over the past year.
Return vs Market: AZN exceeded the UK Market which returned -14.5% over the past year.
|AZN Average Weekly Movement||3.2%|
|Pharmaceuticals Industry Average Movement||6.3%|
|Market Average Movement||5.3%|
|10% most volatile stocks in GB Market||10.7%|
|10% least volatile stocks in GB Market||2.7%|
Stable Share Price: AZN is less volatile than 75% of UK stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: AZN's weekly volatility (3%) has been stable over the past year.
About the Company
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company’s marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19.
AstraZeneca Fundamentals Summary
|AZN fundamental statistics|
Is AZN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AZN income statement (TTM)|
|Cost of Revenue||US$9.86b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 10, 2022
|Earnings per share (EPS)||-0.81|
|Net Profit Margin||-2.85%|
How did AZN perform over the long term?See historical performance and comparison
2.2%Current Dividend Yield
Is AZN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AZN?
Other financial metrics that can be useful for relative valuation.
|What is AZN's n/a Ratio?|
Price to Sales Ratio vs Peers
How does AZN's PS Ratio compare to its peers?
|AZN PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
DPH Dechra Pharmaceuticals
HIK Hikma Pharmaceuticals
HCM HUTCHMED (China)
Price-To-Sales vs Peers: AZN is expensive based on its Price-To-Sales Ratio (3.8x) compared to the peer average (2.7x).
Price to Earnings Ratio vs Industry
How does AZN's PE Ratio compare vs other companies in the GB Pharmaceuticals Industry?
Price-To-Sales vs Industry: AZN is expensive based on its Price-To-Sales Ratio (3.8x) compared to the European Pharmaceuticals industry average (3.7x)
Price to Sales Ratio vs Fair Ratio
What is AZN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||3.8x|
|Fair PS Ratio||20.9x|
Price-To-Sales vs Fair Ratio: AZN is good value based on its Price-To-Sales Ratio (3.8x) compared to the estimated Fair Price-To-Sales Ratio (20.9x).
Share Price vs Fair Value
What is the Fair Price of AZN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: AZN (£100.76) is trading below our estimate of fair value (£237.34)
Significantly Below Fair Value: AZN is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
How is AstraZeneca forecast to perform in the next 1 to 3 years based on estimates from 24 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AZN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.9%).
Earnings vs Market: AZN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AZN is expected to become profitable in the next 3 years.
Revenue vs Market: AZN's revenue (6.9% per year) is forecast to grow faster than the UK market (4.5% per year).
High Growth Revenue: AZN's revenue (6.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AZN's Return on Equity is forecast to be high in 3 years time (29.6%)
Discover growth companies
How has AstraZeneca performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AZN is currently unprofitable.
Growing Profit Margin: AZN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AZN is unprofitable, and losses have increased over the past 5 years at a rate of 23.6% per year.
Accelerating Growth: Unable to compare AZN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AZN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7.1%).
Return on Equity
High ROE: AZN has a negative Return on Equity (-3.47%), as it is currently unprofitable.
Discover strong past performing companies
How is AstraZeneca's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: AZN's short term assets ($20.9B) do not cover its short term liabilities ($21.8B).
Long Term Liabilities: AZN's short term assets ($20.9B) do not cover its long term liabilities ($38.8B).
Debt to Equity History and Analysis
Debt Level: AZN's net debt to equity ratio (71.2%) is considered high.
Reducing Debt: AZN's debt to equity ratio has reduced from 127.8% to 84.8% over the past 5 years.
Debt Coverage: AZN's debt is well covered by operating cash flow (25%).
Interest Coverage: AZN's interest payments on its debt are well covered by EBIT (10.1x coverage).
Discover healthy companies
What is AstraZeneca current dividend yield, its reliability and sustainability?
Dividend Score 3/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
|AstraZeneca Dividend Yield vs Market|
|Market Bottom 25% (GB)||2.1%|
|Market Top 25% (GB)||6.1%|
|Industry Average (Pharmaceuticals)||3.5%|
|Analyst forecast in 3 Years (AstraZeneca)||2.9%|
Notable Dividend: AZN's dividend (2.2%) is higher than the bottom 25% of dividend payers in the UK market (2.1%).
High Dividend: AZN's dividend (2.2%) is low compared to the top 25% of dividend payers in the UK market (6.06%).
Stability and Growth of Payments
Stable Dividend: AZN's dividends per share have been stable in the past 10 years.
Growing Dividend: AZN's dividend payments have fallen over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: AZN is paying a dividend but the company is unprofitable.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonable cash payout ratio (63.8%), AZN's dividend payments are covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Pascal Soriot (63 yo)
Mr. Pascal Soriot, M.B.A., D.V.M., serves as Director at Acerta Pharma B.V. He joined Acerta Pharma in January 2018 as Vice President Research Europe & Site Head of Acerta’s R&D site in The Netherlands. Dr...
CEO Compensation Analysis
|Pascal Soriot's Compensation vs AstraZeneca Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$19m||US$2m|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$22m||US$2m|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||US$20m||US$2m|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||US$16m||US$2m|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||n/a||n/a|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||US$14m||US$2m|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||n/a||n/a|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||US$18m||US$1m|
|Sep 30 2016||n/a||n/a|
|Jun 30 2016||n/a||n/a|
|Mar 31 2016||n/a||n/a|
|Dec 31 2015||US$12m||US$2m|
Compensation vs Market: Pascal's total compensation ($USD18.76M) is above average for companies of similar size in the UK market ($USD5.61M).
Compensation vs Earnings: Pascal's compensation has been consistent with company performance over the past year.
Experienced Management: AZN's management team is seasoned and experienced (9.7 years average tenure).
Experienced Board: AZN's board of directors are considered experienced (5.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|19 May 22||SellUK£934,395||Aradhana Sarin||Individual||18,095||UK£51.64|
|Owner Type||Number of Shares||Ownership Percentage|
|State or Government||2,030,833||0.1%|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
AstraZeneca PLC's employee growth, exchange listings and data sources
- Name: AstraZeneca PLC
- Ticker: AZN
- Exchange: LSE
- Founded: 1992
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: UK£156.127b
- Shares outstanding: 1.55b
- Website: https://www.astrazeneca.com
Number of Employees
- AstraZeneca PLC
- 1 Francis Crick Avenue
- Cambridge Biomedical Campus
- CB2 0AA
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AZN||NasdaqGS (Nasdaq Global Select)||ADR EACH REPR 1 ORD SH SPON||US||USD||May 1993|
|AZNC.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||May 1993|
|AZN||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||GBP||May 1993|
|AZN||OM (OMX Nordic Exchange Stockholm)||Yes||Ordinary Shares||SE||SEK||May 1993|
|AZN N||BMV (Bolsa Mexicana de Valores)||ADR EACH REPR 1 ORD SH SPON||MX||MXN||May 1993|
|0A4J||LSE (London Stock Exchange)||ADR EACH REPR 1 ORD SH SPON||GB||USD||May 1993|
|ZEG||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||May 1993|
|ZEGA||DB (Deutsche Boerse AG)||ADR EACH REPR 1 ORD SH SPON||DE||EUR||May 1993|
|AZNS||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||SEK||May 1993|
|ZEG||XTRA (XETRA Trading Platform)||Yes||Ordinary Shares||DE||EUR||May 1993|
|982352||BRSE (Berne Stock Exchange)||Yes||Ordinary Shares||CH||CHF||May 1993|
|AZNL||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||GBP||May 1993|
|AZN1 N||BMV (Bolsa Mexicana de Valores)||Yes||Ordinary Shares||MX||MXN||May 1993|
|AZN||BASE (Buenos Aires Stock Exchange)||CEDEAR EACH REP 0.5 ADR USD0.25||AR||ARS||Dec 2003|
|AZND||BASE (Buenos Aires Stock Exchange)||CEDEAR EACH REP 0.5 ADR USD0.25||AR||USD||Dec 2003|
|A1ZN34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH 6 REPR 1 ADR||BR||BRL||Sep 2022|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/28 00:00|
|End of Day Share Price||2022/09/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.